Search research articles
Contact Us
Filters
Showing results (371-380 of 501) with videos related to
Page
of 51
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2023
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
Paolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Medicine
|
November 19, 2016
Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy
Katharina C Kaehler, Christine Blome, Andrea Forschner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2016
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab
Alexander Martens, Kilian Wistuba-Hamprecht, Jianda Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial
Axel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2019
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node
Ulrike Leiter, Rudolf Stadler, Cornelia Mauch, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2020
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019
Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2019
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with <i>BRAF</i> <sup>V600</sup>-mutated Metastatic Melanoma
Yibing Yan, Matthew J Wongchenko, Caroline Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2009
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma
Axel Hauschild, Sanjiv S Agarwala, Uwe Trefzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2013
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma
Steven J O'Day, Alexander M M Eggermont, Vanna Chiarion-Sileni, et al.
Frontiers in Immunology
|
July 25, 2022
Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade
Andrea Gaißler, Trine Sundebo Meldgaard, Christina Heeke, et al.
Page
of 51
Search research articles
Search
Showing results (371-380 of 501) with videos related to
Sort By:
Page
of 51
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2023
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
Paolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Medicine
|
November 19, 2016
Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy
Katharina C Kaehler, Christine Blome, Andrea Forschner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2016
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab
Alexander Martens, Kilian Wistuba-Hamprecht, Jianda Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial
Axel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2019
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node
Ulrike Leiter, Rudolf Stadler, Cornelia Mauch, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2020
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019
Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2019
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with <i>BRAF</i> <sup>V600</sup>-mutated Metastatic Melanoma
Yibing Yan, Matthew J Wongchenko, Caroline Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2009
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma
Axel Hauschild, Sanjiv S Agarwala, Uwe Trefzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2013
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma
Steven J O'Day, Alexander M M Eggermont, Vanna Chiarion-Sileni, et al.
Frontiers in Immunology
|
July 25, 2022
Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade
Andrea Gaißler, Trine Sundebo Meldgaard, Christina Heeke, et al.
Page
of 51